Profile data is unavailable for this security.
About the company
Valbiotis SA is a France-based company engaged in the biotechnology industry. The Company specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. It seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The Company prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. It provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
- Revenue in EUR (TTM)4.73m
- Net income in EUR-7.37m
- Incorporated2014
- Employees52.00
- LocationValbiotis SA12F rue Paul VatinePERIGNY 17180FranceFRA
- Phone+33 546286258
- Fax+33 546286258
- Websitehttps://www.valbiotis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GeNeuro SA | 0.00 | -14.76m | 5.06m | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
| Theranexus SA | 0.00 | -6.83m | 7.45m | 19.00 | -- | 3.35 | -- | -- | -1.09 | -1.09 | 0.00 | 0.2863 | 0.00 | -- | -- | 0.00 | -70.79 | -42.66 | -82.29 | -47.97 | -- | -- | -- | -- | -- | -1,058.68 | 0.6212 | -- | -- | -- | -3.97 | -- | -33.23 | -- |
| Quantum Genomics SA | 10.06k | -3.17m | 7.74m | 3.00 | -- | 8.86 | -- | 769.17 | -0.091 | -0.091 | 0.0003 | 0.0125 | 0.0007 | -- | 0.0016 | 3,353.33 | -23.14 | -60.77 | -95.19 | -102.24 | -14,205.07 | -3,548.91 | -31,520.38 | -3,374.13 | -- | -146.53 | 0.8615 | -- | -98.34 | -- | 87.28 | -- | -- | -- |
| Acticor Biotech SA | 0.00 | -18.65m | 9.45m | 24.00 | -- | 20.12 | -- | -- | -1.68 | -1.68 | 0.00 | 0.0298 | 0.00 | -- | -- | 0.00 | -145.59 | -- | -297.22 | -- | -- | -- | -- | -- | -- | -9.32 | 0.9504 | -- | -- | -- | -25.94 | -- | -- | -- |
| Plant Advanced Technologies PAT SA | 1.68m | 79.16k | 15.53m | 27.00 | 193.24 | 1.81 | 26.78 | 9.23 | 0.0725 | 0.0725 | 1.54 | 7.73 | 0.1118 | -0.4123 | 1.60 | 62,278.52 | 0.5262 | -3.53 | 0.6534 | -4.39 | 128.03 | 134.21 | 4.71 | -33.16 | 0.4183 | -15.32 | 0.3402 | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
| Oncodesign Precision Medicine Opm SA | 1.07m | -8.09m | 18.46m | 22.00 | -- | 4.57 | -- | 17.22 | -0.4863 | -0.4863 | 0.0645 | 0.2219 | 0.0613 | -- | 1.39 | 48,735.00 | -46.23 | -- | -63.87 | -- | 130.48 | -- | -754.61 | -- | -- | -- | 0.7052 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Phaxiam Therapeutics SA | 1.33m | -23.49m | 20.16m | 51.00 | -- | 0.5184 | -- | 15.20 | -5.14 | -5.14 | 0.2901 | 3.90 | 0.0273 | -- | 14.82 | 26,000.00 | -48.37 | -50.69 | -66.94 | -66.25 | -- | -- | -1,771.42 | -1,009.09 | -- | -70.21 | 0.3412 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| Poxel SA | 1.55m | -44.24m | 23.51m | 30.00 | -- | -- | -- | 15.21 | -1.44 | -1.44 | 0.0507 | -1.22 | 0.0597 | -- | 5.42 | 30,920.00 | -170.71 | -31.97 | -432.50 | -55.94 | 0.1294 | -- | -2,861.58 | -101.47 | -- | -4.08 | 11.28 | -- | -94.97 | -33.77 | -32.13 | -- | -8.49 | -- |
| Valbiotis SA | 4.73m | -7.37m | 24.01m | 52.00 | -- | 1.22 | -- | 5.07 | -0.5904 | -0.5904 | 0.3798 | 1.24 | 0.1564 | 3.36 | 17.83 | 91,019.23 | -24.35 | -32.92 | -33.77 | -46.36 | 48.76 | 53.15 | -155.67 | -418.87 | 3.38 | -38.19 | 0.2598 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
| Nfl Biosciences SAS | 0.00 | -3.48m | 26.01m | 3.00 | -- | 6.54 | -- | -- | -0.5396 | -0.5396 | 0.00 | 0.4097 | 0.00 | -- | -- | 0.00 | -80.79 | -- | -125.59 | -- | -- | -- | -- | -- | -- | -- | 0.0228 | -- | -- | -- | -149.78 | -- | -- | -- |
| Predilife SA | 317.79k | -4.22m | 26.04m | 19.00 | -- | -- | -- | 81.95 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
| Gensight Biologics SA | 1.27m | -26.22m | 32.28m | 16.00 | -- | -- | -- | 25.48 | -0.5427 | -0.5427 | 0.0269 | -0.4726 | 0.0723 | -- | 2,534.00 | 79,187.50 | -149.52 | -79.44 | -- | -144.54 | -- | -- | -2,069.53 | -1,036.27 | -- | -- | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
Data as of Jul 05 2024. Currency figures normalised to Valbiotis SA's reporting currency: Euro EUR
10.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| OFI Invest Asset Management SAas of 29 Feb 2024 | 600.47k | 3.80% |
| Amiral Gestion SAas of 30 Jun 2023 | 371.36k | 2.35% |
| Talence Gestion SASas of 30 Apr 2024 | 187.84k | 1.19% |
| UBS LA MAISON de Gestionas of 30 Dec 2022 | 150.00k | 0.95% |
| Friedland Gestion SASas of 29 Feb 2024 | 119.78k | 0.76% |
| Hermitage Gestion Priv�e SAas of 31 Dec 2022 | 80.00k | 0.51% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 79.99k | 0.51% |
| HSBC Global Asset Management (France) SAas of 31 May 2024 | 56.78k | 0.36% |
| Pure Capital SAas of 31 Dec 2023 | 44.84k | 0.28% |
| MW Gestion SAas of 31 Dec 2023 | 33.63k | 0.21% |
More ▼
Data from 31 Dec 2022 - 28 Jun 2024Source: FactSet Research Systems Inc.
